Of note, after initial tumor regression, some PTPRZ1-TCR-T-treated animals experienced tumor recurrence starting from day 42 onwards, yet by the predefined experimental endpoint, 33% (3 out of 9) of PTPRZ1-TCR-T cell-treated animals remained tumor-free, resulting in prolonged survival (Supplementary Fig. 7c, d). Here, PTPRZ1 is linked to neoplasm.